Loading quotes...
Forecast
The analysts' average price target is €4.54 (+260.32%). The median is €4.54 (+260.32%).
| Buy |
Â
7 |
| Hold |
Â
1 |
| Sell |
Â
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Neuronetics reports Q2 2026 revenue growth, narrows guidance and advances toward profitability
Neuronetics posted Q2 revenue of $41.6 million, up ~9% year-over-year, driven by Greenbrook clinics ($26.9 million, +16.8%) while NeuroStar revenue declined to $14.7 million as the company shifts customers from a session model toward capital sales and leasing. Gross margin improved to 51.1% and adjusted EBITDA was positive $0.3 million, with net loss narrowing to $3.4 million; cash totaled $25 million at quarter end after $7.6 million raised via an ATM. Management narrowed full-year revenue guidance to $160–164 million, lowered OPEX guidance and expects reduced cash burn as it scales Greenbrook, rolls out new NeuroStar commercial options and pursues interventional psychiatry opportunities. » More on finance.yahoo.com
Neuronetics: stock jumps after strong quarterly results and turnaround hopes
For Q2 2026 Neuronetics reported revenue of $41.6 million (+9.1% y/y) and a net loss of $3.4 million (‑$0.05 per share), markedly better than the consensus estimate of about ‑$0.12. The clinic segment Greenbrook contributed $26.9 million (+16.8%) and was a key driver of growth; adjusted EBITDA improved to $0.3 million versus ‑$5.6 million a year earlier, and the cash outflow from operating and investing activities fell to $1.4 million. Management changes, including a new CFO, boosted confidence in the turnaround strategy, after which the stock rose about 24% in premarket trading. » More on de.investing.com
Neuronetics amends adviser agreement for interim principal financial and accounting officer and raises monthly compensation
Neuronetics has revised the adviser agreement with interim Principal Financial and Accounting Officer Francis X. Brown III effective May 18, 2026; Brown will remain in office until a full-time controller and head of finance is appointed or until a mutually agreed written date. Compensation was adjusted from $25,000 to a monthly flat fee of $26,000. The company also reported Q1 2026 revenue of $34.5 million (above analyst expectations) but missed the EPS target; Neuronetics announced a partnership with ANT Neuro to integrate neuronavigation technology. » More on de.investing.com
Neuronetics integrates ANT Neuro neuronavigation into NeuroStar system
Neuronetics is partnering with ANT Neuro to integrate the FDA-cleared neuronavigation system visor2 into the NeuroStar Advanced Therapy System for TMS. The technology provides real-time tracking and patient-specific 3D visualization to improve positioning, consistency and safety of treatments. The partnership will be presented later in May at the American Psychiatric Association annual meeting and in June at the Clinical TMS Society; a broader market rollout is planned for the second half of 2026. Neuronetics operates Greenbrook TMS centers, has a market capitalization of $105 million and has recently faced a steep share-price decline despite revenue growth. » More on de.investing.com
Neuronetics increases revenue but misses EPS target in Q1 2026
Neuronetics reported Q1 2026 revenue of $34.5 million (+8% YoY), slightly above expectations, while EPS of -$0.16 missed the forecast of -$0.13. U.S. clinic revenues rose 15%, the NeuroStar segment fell 3%. Gross margin declined 230 basis points to 46.9%, operating expenses fell 6%, and net loss narrowed to $10.8 million. The company reaffirmed full-year guidance of $160–166 million, expects improved operating cash flow, and plans annual cost savings of $2.5–3.0 million; the stock rose 2.5% premarket. » More on de.investing.com
Financials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 37.05m | 16.56% |
| Gross profit | 19.33m | 32.56% |
| Net profit | -1.49m | 80.62% |
| EBITDA | 1.13m | 120.66% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €98.04m |
Number of shares | 77.73m |
52-week high/low | €3.12 - €0.73 |
| Dividends | No |
Beta | 1.20 |
P/E ratio | -4.32 |
PEG ratio | -0.04 |
P/B ratio | 5.72 |
P/S ratio | 0.68 |
Company profile
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
| Name | NEURONETICS INC. DL-,01 |
| CEO | Daniel L. Reuvers |
| Headquarters | Malvern,
pa USA |
| Website | |
| Sector | Consumer Discretionary |
| Industry | Household Durables |
| IPO | 28/06/2018 |
| Employees | 658 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | STIM |
Frankfurt | NRC.F |
DĂĽsseldorf | NRC.DU |
MĂĽnchen | NRC.MU |